Research programme: cancer vaccines - Vaxenta

Drug Profile

Research programme: cancer vaccines - Vaxenta

Alternative Names: Placental vaccination therapy - Vaxenta; XenUvaX

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxenta Biotechnologies
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Malignant melanoma

Most Recent Events

  • 20 Jul 2016 Preclinical development is ongoing in USA
  • 01 Jan 2014 Preclinical trials in Colorectal cancer in USA (unspecified route)
  • 01 Jan 2014 Preclinical trials in Malignant melanoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top